Dapagliflozin provides additional benefits to improve hepatic function and glucose control for patients with type 2 diabetes and non-alcoholic fatty liver disease, as shown by the by the reduction in ALT, AST, fasting glucose and HbA1c. This evidence concerns the gene GPT and type 2 diabetes mellitus.